GE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read More
BigBio Communications, publisher of Big4Bio, the premier aggregator of financial, clinical, and business news from the top life sciences regions, is proud to announce the upcoming launch of “BioStartup News” (biostartup.news), a weekly newsletter recapping the latest developments of U.S.-based life sciences startups.
Read More
GE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read More
GE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read More
During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for this collaborative research project is made possible with the financial support of the ministère de l’Économie et de l’Innovation (MEI) who will be providing $1.36M as part of CQDM’s SynergiQC program.
Read More
Bromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read More
Bromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read More
Bromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read More
GE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read More
adMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership to train industry-ready talent for Canada’s biopharmaceutical manufacturing sector.
Read More
GE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read More
JAMP Pharma Group, the Québec leader in prescription volume, launches Guanfacine XR, a niche generic that is equivalent to the reference product in size and appearance, offering an affordable alternative.
Read More
BigBio Communications, publisher of Big4Bio, the premier aggregator of financial, clinical, and business news from the top life sciences regions, is proud to announce the upcoming launch of “BioStartup News” (biostartup.news), a weekly newsletter recapping the latest developments of U.S.-based life sciences startups.
Read More
Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies’ from its current partner contract sales organization. Higher employee engagement and retention, greater ability to attract top talent and lower turnover rate expected from the move
Read More
JAMP Pharma Group, the Québec leader in prescription volume, launches Guanfacine XR, a niche generic that is equivalent to the reference product in size and appearance, offering an affordable alternative.
Read More
Find Therapeutics Inc. ('Find') is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer.
Read More
Hoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for EVRYSDI® (risdiplam), a pre-mRNA splicing modifier of survival of motor neuron 2 (SMN2) designed to treat SMA, indicated for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.1
Read More
“We are pleased to close our first financing and to welcome Frederic Ors as lead investor and strategic advisor to Saguaro. Frederic is a well-recognized executive with a track-record of successfully growing biotech companies,” said Louis Turcotte Co-Founder & Chief Executive Officer. “Frederic shares our vision on the potential of next-generation technologies to make drug discovery more successful and we are looking forward to benefit from his experience and network.”
Read More
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients
Read More
Celltrion Healthcare Canada Limited is very pleased to announce that Health Canada granted a notice of compliance (NOC) on December 24, 2021 for Yuflyma™, a high-concentration (100mg/mL), low-volume, citrate-free, and latex-free biosimilar to Humira® (adalimumab). Yuflyma™ is approved across all ten intended indications for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis, and pediatric uveitis.1
Read More